ACP Investor's  Instablog

ACP Investor
Send Message
I have a background in corporate finance and M&A with over 12 years of experience advising on complex transactions across various industries. From an investment point of view, I look at deep value and special situations with defined near term catalysts where the upside outweighs the potential... More
  • MusclePharm (MSLP) Acquires Biozone (BZNE) 0 comments
    Nov 13, 2013 12:46 PM | about stocks: MSLP, COCP



    Entry into a Material Definitive Agreement, Financial Statements an

    Item 1.01 Entry into a Material Definitive Agreement.

    On November 12, 2013, Biozone Pharmaceuticals, Inc. (the "Company"), Biozone Laboratories, Inc. ("Bio Lab"), Baker Cummins Corp. ("BCC") (the Company, Bio Lab and BCC are collectively referred to as "Biozone"), Brian Keller, MusclePharm Corporation ("Musclepharm") and Biozone Laboratories, Inc. ("Acquisition Co."), a newly formed subsidiary of Musclepharm, entered into an Asset Purchase Agreement (the "Agreement"). The Agreement provides that Acquisition Co. will acquire substantially all of the operating assets of Biozone including the QuSomes, HyperSorb and EquaSomes drug delivery technologies (excluding certain assets including cash on hand) for 1,200,000 shares of Musclepharm's common stock. Of the 1,200,000 shares being issued under the Agreement, (i) 600,000 of the shares will be issued to the Company upon closing and (ii) 600,000 of the shares (the "Escrowed Shares") will be placed in escrow for nine months from the date of closing (the "Escrow Period"). During the Escrow Period, Musclepharm will have the option to purchase the Escrowed Shares at $10.00 per share in cash. The Escrowed Shares will also back-stop potential indemnification claims that Acquisition Co. may have under the Agreement.

    The Agreement contains representations, warranties, covenants and termination rights that are customary for a transaction of this type. The closing of the Agreement is subject to several closing conditions including the Company receiving shareholder approval, Musclepharm's receipt of a fairness opinion, Mr. Brian Keller, the Company's President and Chief Scientific Officer, entering into a new two-year Employment Agreement with Musclepharm and other customary closing conditions.

    The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the Agreement, which is filed as Exhibit 2.1 hereto, and is incorporated herein by reference.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit No. Description


    Disclosure: I am long OTCQB:MSLP.

    Stocks: MSLP, COCP
Back To ACP Investor's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.